Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 17/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3098258 | 0.88 | PDE3B (0.50) | HRH3KCNH2PDE3BPDE3AMAP4K4 | |
| SCHEMBL3090848 | 0.75 | HPGD (0.43) | — | |
| SCHEMBL7290491 | 0.72 | PDE3B (0.57) | HRH3PDE3BPDE3A | |
| SCHEMBL5677056 | 0.70 | KEAP1 (0.56) | HRH3KCNH2 | |
| SCHEMBL1277385 | 0.69 | CPB2 (0.41) | PDE3BPDE3ACA1CA2 | |
| SCHEMBL1698930 | 0.69 | CPB1 (0.39) | HRH3PDE3BPDE3ACA1CA2 | |
| Hydrochloric Acid SCHEMBL1277342 | 0.69 | CPB2 (0.41) | PDE3BPDE3ACA1CA2 | |
| SCHEMBL28187390 | 0.68 | CPB2 (0.54) | PDE3BPDE3A | |
| SCHEMBL5287962 | 0.68 | HRH3 (0.51) | HRH3KCNH2 | |
| SCHEMBL3089686 | 0.67 | HRH3 (0.54) | HRH3KCNH2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234352-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2010-09-16 | — | — | US | disclosed |
| US-7696352-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| EP-2114928-A2 | THIOPHENE CARBOXAMIDES AS FACTOR XA INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008086188-A2 | THIOPHENE CARBOXAMIDES AS FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| US-20070185092-A1 | FACTOR Xa INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185092-A1 | FACTOR Xa INHIBITORS | TFPI, F12, F11 | HRH3 1587/4885KCNH2 1993/4885PDE3B 131/4885 |
| US-20100234352-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | HRH3 1587/4885KCNH2 1993/4885PDE3B 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.